Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02937272 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3200882 in Participants With Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 223
- Enrollment target
- 18
- Study locations
NCT02937272 is a Phase 1 study of Solid Tumor that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 223 participants, roughly in line with the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target. The trial reports 18 study locations across 11 states.
The verdict
NCT02937272, a Phase 1 study of Solid Tumor, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 223 participants
- Enrollment target
- 18
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG nab-Paclitaxel
- DRUG LY3200882
- DRUG LY3300054
Study Locations (18)
Other
- CHRU de Lille - Lille
- Gustave Roussy - Villejuif
- Charité Campus Virchow-Klinikum - Berlin
- Ospedale Policlinico Giambattista Rossi, Borgo Roma - Verona
- Hospital Universitari Vall d'Hebron - Barcelona
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Clínico Universitario de Valencia - Valencia
New South Wales
- Calvary Mater Newcastle - Newcastle
- St Vincent's Hospital Sydney - Sydney
Kentucky
- University of Louisville - Louisville
New York
- Weill Cornell Medical College - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
Queensland
- Greenslopes Private Hospital - Greenslopes
Kowloon
- Princess Margaret Hospital (Ontario) - Lai Chi Kok
Cedex 10
- Hopital Saint-Louis - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2016-11-21 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02937272
The ClinicalTrials.gov registry entry for NCT02937272 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT02937272 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Other, New South Wales, Kentucky.
Frequently Asked Questions
What is clinical trial NCT02937272 about?
NCT02937272 is a clinical study titled "A Study of LY3200882 in Participants With Solid Tumors". The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
What is the current status of trial NCT02937272?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 223 participants. The study started on 2016-11-21. Estimated completion is 2026-08.
What conditions does trial NCT02937272 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT02937272?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), nab-Paclitaxel (DRUG), LY3200882 (DRUG), LY3300054 (DRUG).
Who is sponsoring clinical trial NCT02937272?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02937272 being conducted?
This trial has 18 study locations across Kentucky, New York, Texas, New South Wales, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.